Emerging drugs for the treatment of uveitis

Theresa G. Leung, Jennifer E. Thorne

Research output: Contribution to journalReview article

Abstract

Introduction: Uveitis is a potentially visually debilitating disease when untreated or poorly controlled. Chronic intermediate, posterior, or panuveitis often requires systemic immunosuppressive therapy to prevent such visual loss. Areas covered: This review discusses existing treatments for ocular inflammation including corticosteroids, antimetabolites, alkylating agents, T-cell inhibitors, and biologic agents. Potential drugs being studied in clinical trials are introducing new routes for local corticosteroid delivery, and novel immunomodulators are exploring new targets of the inflammatory cascade. Expert opinion: Treatment options for uveitis have expanded from even a decade ago. However, more clinical trials and research are needed to further our understanding of the mechanisms of ocular inflammation and the safety and efficacy of novel therapies.

Original languageEnglish (US)
Pages (from-to)513-521
Number of pages9
JournalExpert Opinion on Emerging Drugs
Volume18
Issue number4
DOIs
StatePublished - Dec 1 2013

Keywords

  • Biologics
  • Corticosteroids
  • Immunosuppression
  • Ocular inflammation
  • Uveitis

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Emerging drugs for the treatment of uveitis'. Together they form a unique fingerprint.

  • Cite this